Van ECK Associates Corp Has $5.94 Million Stake in Charles River Laboratories International, Inc. $CRL

Van ECK Associates Corp trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 28.8% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,210 shares of the medical research company’s stock after selling 10,616 shares during the quarter. Van ECK Associates Corp owned approximately 0.05% of Charles River Laboratories International worth $5,944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Avidity Partners Management LP bought a new stake in Charles River Laboratories International in the first quarter worth approximately $1,670,000. Handelsbanken Fonder AB raised its holdings in Charles River Laboratories International by 36.9% during the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock worth $4,378,000 after buying an additional 5,200 shares during the last quarter. California State Teachers Retirement System lifted its position in Charles River Laboratories International by 21.8% in the 1st quarter. California State Teachers Retirement System now owns 56,972 shares of the medical research company’s stock valued at $9,828,000 after acquiring an additional 10,207 shares in the last quarter. Maverick Capital Ltd. bought a new position in shares of Charles River Laboratories International in the first quarter valued at approximately $1,411,000. Finally, WINTON GROUP Ltd bought a new position in Charles River Laboratories International during the 4th quarter valued at $9,209,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Robert W. Baird set a $291.00 target price on shares of Charles River Laboratories International in a research report on Thursday, August 6th. Morgan Stanley upped their price objective on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $180.00 to $310.00 in a report on Thursday, August 6th. Sanford C. Bernstein set a $250.00 price objective on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Finally, Weiss Ratings raised Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. Twelve analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $255.65.

Charles River Laboratories International Trading Up 3.3%

Shares of CRL stock opened at $291.79 on Thursday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $303.30. The stock has a market capitalization of $13.93 billion, a PE ratio of -60.16, a P/E/G ratio of 2.77 and a beta of 1.40. The business has a 50-day moving average of $251.93 and a 200 day moving average of $199.91.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm’s revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the previous year, the firm earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Insider Transactions at Charles River Laboratories International

In related news, Director James C. Foster sold 33,561 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $300.00, for a total transaction of $10,068,300.00. Following the transaction, the director owned 31,596 shares in the company, valued at $9,478,800. The trade was a 51.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares in the company, valued at $10,080,038.70. This trade represents a 15.29% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 165,990 shares of company stock worth $42,606,388. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.